



# HYDROCEPHALUS IN MINNESOTA

HYDROCEPHALUS IS A CHRONIC NEUROLOGICAL CONDITION THAT HAS NO CURE. ANYONE AT ANY TIME CAN DEVELOP HYDROCEPHALUS, FROM INFANTS TO SENIORS. THE ONLY TREATMENT REQUIRES BRAIN SURGERY.



## CONTRIBUTIONS TOWARD A BETTER TOMORROW

### CEROVATIONS, LLC

2019 NIH NINDS **\$498,034**

Cerebral Spinal Fluid Shunt System with Dual Lumen Distal Catheter Redundancy to Minimize Revision Surgery

### INNOVATIVE SURFACE TECHNOLOGIES, INC.

2020 NIH NINDS **\$231,993**

Ultra-low attachment coatings to maintain CSF shunt patency

### MINNETRONIX, INC.

2020 NIH NINDS **\$1,499,976**

Automation of Extracorporeal Filtration of Subarachnoid Hemorrhage via Spinal Catheter

2021 NIH NINDS **\$395,323**

Automation of Extracorporeal Filtration of Subarachnoid Hemorrhage via Spinal Catheter

### UNIVERSITY OF MINNESOTA

2021 NIH NINDS **\$328,308**

L1CAM adhesion and signaling pathways in *C. elegans*

### MAYO CLINIC

2021-2026 NIH NINDS Grant **\$14,000,000**

Placebo-Controlled Effectiveness of Idiopathic Normal Pressure Hydrocephalus Shunting. Principal Investigator: Elder, Benjamin

## TWIN CITIES


### WALK TO END HYDROCEPHALUS

Buck Hill, Burnsville

Saturday, October 5, 2024, Buck Hill

[twincitieswalk@hydroassoc.org](mailto:twincitieswalk@hydroassoc.org)

[hydroassoc.org/twincitieswalk](http://hydroassoc.org/twincitieswalk)



## MAKING AN IMPACT

### The Big Picture

- 2 Clinical Research Networks
- 1 Basic & Translational Research Network
- 2 Biobanks
- 1 Hydrocephalus Patient-Powered Registry
- 36% Decrease in Shunt Infection Rates
- 11 Preclinical Drug Therapies in testing
- 1 New Patent for a Drug Target
- 1 FDA Investigational New Drug Application



## COMMUNITY SUPPORT GROUPS

Minneapolis Community Network

State-wide Online Facebook Group

One-on-one Peer Support Volunteers